Clorox (CLX) is back in focus after Chair and CEO Linda Rendle said she will step down for health reasons, as the board begins a formal CEO search while maintaining her involvement for continuity.

The CEO transition headlines sit alongside a recent earnings-related bounce, with the stock seeing a 6.81% 7 day share price return but still showing a 22.00% decline in 1 year total shareholder return, so longer term momentum has been weak.

If this kind of leadership change has you thinking about where else to put fresh capital to work, it could be a good moment to scan 20 top founder-led companies

With Clorox shares up 6.81% over the past week but still down 22.00% on a 1 year view, the key question now is simple: are investors looking at an undervalued consumer staple or a stock that already reflects its future growth?

Most Popular Narrative: 18% Undervalued

The most followed narrative puts Clorox’s fair value at $115.47, compared with the last close at $95.16, which sets up a clear valuation gap for investors to assess.

The full-scale implementation of a modern ERP system is expected to drive long-term operational efficiencies, improving supply chain visibility, speeding innovation cycles, and reducing structural costs, which should support margin expansion and sustained earnings growth once short-term transition noise normalizes.

Want to see what sits behind that earnings story and fair value gap? The narrative leans heavily on revenue growth, margin lift, and a future profit multiple that assumes the market will pay up for those outcomes. The exact mix of those inputs might surprise you.

Result: Fair Value of $115.47 (UNDERVALUED)

However, this depends on consumer demand stabilising and price competition easing. Weaker categories or heavier discounting could pressure margins and challenge the upbeat fair value story.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With sentiment split between recovery potential and lingering risks, it makes sense to look at the figures yourself, be prepared to act quickly if needed, and carefully weigh the balance of 4 key rewards and 2 important warning signs

Ready to hunt for your next idea?

Do not stop with one stock story when there are plenty of other opportunities you can size up quickly using focused stock lists built from clear, simple criteria.

• Target stability with companies that feature strong finances and lower risk profiles through the 62 resilient stocks with low risk scores.
• Spot potential mispricings by scanning for quality stocks trading below their estimated worth using the 47 high quality undervalued stocks.
• Prioritise resilience by focusing on businesses with healthy balance sheets through the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.